Stock Region Penny Picks
Cures, Cash & Cutting-Edge Tech.
Stock Region Penny Picks Watchlist
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: Hold on tight! Before we dive in, please remember this is a watchlist, not financial advice. The content here is for informational and entertainment purposes only. We’re just a bunch of market enthusiasts sharing what’s catching our eye. Always do your own research and consult with a professional before making any investment decisions. Trading stocks, especially the ones we watch, comes with significant risk.
The markets felt like every corner of the biotech and tech worlds was buzzing with game-changing news. From incredible medical breakthroughs to massive financing deals, there was no shortage of excitement. Let’s break down the tickers that made our heads turn today.
Today’s Movers & Shakers
$CANF - Can-Fite Therapeutics
Wow. Just... wow. Can-Fite announced a 9-YEAR SURVIVAL with a complete cure in an advanced liver cancer patient using their drug, Namodenoson. This isn’t just a “positive result”; this is the kind of news that gives you goosebumps. A complete cure in an advanced case is the holy grail. This puts Can-Fite in a whole new light for me. A truly monumental achievement.
$BTQ - BTQ Technologies
Quantum computing meets AI? Sign me up. BTQ’s QPerfect division launched a GPU-accelerated platform with NVIDIA CUDA-Q compatibility. Partnering with a giant like NVIDIA to push the boundaries of quantum computing is a massive power move. This could be a foundational technology for the future, and BTQ is right in the middle of it.
$GDTC - CytoMed Therapeutics
CytoMed just completed an acquisition of T-cell technology to treat cancers in China and India. This is huge from a market perspective. We’re talking about two of the world’s largest populations. Gaining a foothold there with advanced cancer-fighting tech could be a company-maker. A very strategic and potentially lucrative move.
$ICCM - IceCure Medical
More great news on the cancer front! IceCure’s ProSense® system got regulatory approval in Switzerland. This system uses cryoablation (freezing tumors) for a range of cancers. Getting the green light in a country with such high medical standards is a major vote of confidence.
$GLMD - Galmed Pharmaceuticals
Galmed announced “meaningful” top-line results from its Phase 1 study of Aramchol meglumine. While Phase 1 is early, positive bioavailability data is a critical first step. It shows the drug is getting where it needs to go in the body. A solid, foundational win for their pipeline.
$ONFO - Onfolio Holdings
Show me the money! Onfolio secured up to $300 MILLION in financing. That is a gigantic pile of cash that can fuel acquisitions, growth, and major strategic initiatives. A funding deal of this size tells you that someone with very deep pockets believes in their vision.
$CMND - Clearmind Medicine
Clearmind announced positive top-line results from its FDA-approved trial for Alcohol Use Disorder. Tackling addiction is an enormous challenge, and seeing positive results from a clinical trial is always encouraging. This has the potential to impact millions of lives.
$LPCN - Lipocine Inc.
Lipocine highlighted a promising interim safety profile for its drug targeting postpartum depression (PPD). PPD is a serious and often overlooked condition. A safe and effective treatment would be a game-changer for new mothers, and Lipocine is making important progress.
$WLDS - Wearable Devices
This one sounds like something out of a sci-fi movie. Wearable Devices unveiled a new tech that can estimate weight just by reading muscle signals (EMG). This is next-level neural-interface IP. The potential applications in fitness, health, and beyond are mind-boggling.
$ZSPC - zSpace
zSpace is taking augmented reality learning to the next level with its new zStylus One. An advanced stylus with embedded sensors and machine learning? It sounds like they are making AR more intuitive and accessible for education. This could be a key piece of the puzzle for mainstream AR adoption.
$ELDN - Eledon Pharmaceuticals
Eledon reported preliminary data from a Type 1 Diabetes trial. Using tegoprubart after islet transplantation is cutting-edge stuff. While it’s early data from just six patients, any positive movement in the fight against diabetes is a big deal and worth watching closely.
$KZIA - Kazia Therapeutics
Kazia reported an initial complete response in metastatic triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease. Seeing a complete response in such a difficult-to-treat cancer is incredibly promising and a huge win for the company’s pipeline.
What a list! It’s days like this that remind us why we love watching the markets—innovation is happening everywhere. Keep these on your radar and let’s see where they go.
Happy trading,
The Stock Region Team
Final Disclaimer: Seriously, this is not a recommendation to buy or sell anything. These are just our opinions based on publicly available news. The stock market is a wild ride, and you are solely responsible for your own financial decisions. Please be smart, be safe, and do your homework.